Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $29,054 | $37,549 | $42,408 | $44,049 |
| Short-Term Investments | $0 | $0 | $62 | $687 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $842 | $491 | $710 | $1,549 |
| Total Curr. Assets | $29,896 | $38,040 | $43,230 | $46,285 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $29,896 | $38,040 | $43,230 | $46,285 |
| Liabilities | – | – | – | – |
| Payables | $1,565 | $1,375 | $1,135 | $1,029 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5,177 | $4,874 | $4,431 | $1,986 |
| Total Curr. Liab. | $6,742 | $6,249 | $5,566 | $3,015 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $6,742 | $6,249 | $5,566 | $3,015 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $31 | $31 | $31 | $31 |
| Retained Earnings | -$164,259 | -$155,362 | -$149,243 | -$143,383 |
| AOCI | $0 | $0 | -$1 | -$7 |
| Other Equity | $187,382 | $187,122 | $186,877 | $186,629 |
| Total Equity | $23,154 | $31,791 | $37,664 | $43,270 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $29,896 | $38,040 | $43,230 | $46,285 |
| Net Debt | -$29,054 | -$37,549 | -$42,408 | -$44,049 |